Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) - Polish population

Archives of Medical Science

Volumn 11, Issue 4, 2015, Pages 743-750

  Straburzyńska Migaj, Ewa ^a   Kałuzna Oleksy, Marta ^a   Pietro Maggioni, Aldo ^b   Grajek, Stefan ^a   Opolski, Grzegorz ^c   Ponikowski, Piotr ^d   Jankowska, Ewa ^d   Balsam, Paweł ^c   Poloński, Lech ^e   Drozdz, Jarosław ^f  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b ANMCO RESEARCH CENTER   (Italy)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

B blocker; Chronic heart failure; Chronic obstructive pulmonary disease

Indexed keywords

BISOPROLOL; CARVEDILOL; METOPROLOL; NEBIVOLOL;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; FOLLOW UP; HEALTH SURVEY; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; NEW YORK HEART ASSOCIATION CLASS; OUTPATIENT; PILOT STUDY; POLAND; SMOKING; TREATMENT OUTCOME;

EID: 84939130364     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2014.47878     Document Type: Article

References (36)

1. Hawkins NM, Petrie MC, Jhund MC, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11: 130-9.
2. Mascarenhas J, Louren P, Lopes R, et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic, and prognostic implications. Am Heart J 2008; 155: 521-5.
3. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26: 1887-94.
4. Rusinaru D, Saaidi I, Godard S, et al. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol 2008; 101: 353-8.
5. Macchia A, Monte S, Romero M, et al. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalized for chronic heart failure. Eur J Heart Fail 2007; 9: 942-8.
6. Hawkins NM, Huang Z, Pieper KS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: Analysis of the Valsartan in The Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2009; 11: 292-8.
7. Staszewsky L, Wong M, Masson S, et al. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail 2007; 13: 797-804.
8. Hawkins NM, Jhund PS, Simpson CR, et al. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail 2010; 12: 17-24.
9. Mentz RJ, Schulte PJ, Fleg JL, et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: Findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Train-Ning (HF-ACTION). Am Heart J 2013; 165: 193-9.
10. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290: 2581-7.
11. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003; 42: 1226-33.
12. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: A population-based study. Arch Intern Med 2002; 162: 1689-94.
13. O'Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: An analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008; 156: 662-73.
14. Siirila-Waris K, Laussus J, Merlin J, et al. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 2006; 27: 3011-7.
15. Mentz RJ, Fiuzat M, Wojdyla DM, et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. Eur J Heart Fail 2012; 14: 395-403.
16. Mentz RJ, Schmidt PH, Kwasny MJ, et al. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: An analysis of the EVEREST trial. J Card Fail 2012; 18: 515-23.
17. Dahlström U. Frequent non-cardiac comorbidities in patients with chronic heart failure. Eur J Heart Fail 2005; 7: 309-16.
18. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: A meta-analysis. Respir Med 2003; 97: 1094-101.
19. van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of beta-blockers in COPD: A concern for nonselective beta-blockers. Chest 2005; 127: 818-24.
20. Shelton RJ, Rigby AS, Cleland JG. Effect of community heart failure clinic on the uptake of beta-blockers in patients with obstructive airways disease and heart failure. Heart 2006; 92: 331-6.
21. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: A randomized crossover trial. J Am Coll Cardiol 2010; 55: 1780-7.
22. Lainscak M, Podbregar M, Kovacic D, et al. Differences between bisoprolol and carvediolol in patients with chronic heart failure and chronic obstructive pulmonary disease: A randomized trial. Respir Med 2011; 105 (Suppl. 1): S44-9.
23. Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. J Am Coll Cardiol 2011; 57: 2127-38.
24. Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010; 12: 1076-84.
25. Sosnowska-Pasiarska B, Bartkowiak R, Woakowska-Kapon B, et al. Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot). Kardiol Pol 2013; 71: 234-40.
26. Rywik TM, Koodziej P, Targoski R, et al. Characteristics of heart failure population in Poland: ZOPAN, a multicentre national programme. Kardiol Pol 2011; 69: 24-31.
27. Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013; 15: 808-17.
28. Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013; 15: 1173-84.
29. Antczak A, Ciebiada M, Pietras T, et al. Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Arch Med Sci 2012; 8: 277-85.
30. Kwon BJ, Kim DB, Jang SW, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail 2010; 12: 1339-44.
31. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. Updated Feb 2013. Available from: http://www.goldcopd.org/Guidelines/guidelines-resources. html.
32. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847.
33. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the Amer ican College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee of Update the 2001 Guidelines for Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the Interventional Society. Circulation 2005; 12: e154-235.
34. The Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006; 12: 10-38.
35. Stefan MS, Rothberg MB, Pirya A, et al. Association between beta-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischemic heart disease, heart failure or hypertension. Thorax 2012; 67: 977-84.
36. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al. Unrecognized ventricular dysfunction in COPD. Eur Repir J 2012; 39: 51-8.